Healthy
Conditions
Brief summary
1. To evaluate the pharmacokinetics (PK) and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers. 2. To evaluate the safety and tolerability of TG-2349 in healthy volunteers. 3. To evaluate the ethnic differences in PK and safety between East Asian and Caucasian volunteers.
Detailed description
TG-2349 oral solution has been investigated in a phase I/IIa study (study number: TG-2349-01) in healthy volunteers and patients with chronic hepatitis C (CHC) infection. The study demonstrated that TG-2349 was safe and well-tolerated when given to healthy volunteers at single oral doses up to 800 mg, and at five-consecutive daily oral doses up to 600 mg. Co-administration of TG-2349 with food resulted in a significant increase in bioavailability, and therefore concomitant food intake with dosing is recommended. To further advance the clinical development of TG-2349, a new capsule formulation was developed to replace the current TG-2349 oral solution. The objectives of this study (study number: TG-2349-02) are to evaluate the PK and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers, and to evaluate the safety, tolerability, and ethnic differences of the TG-2349 capsule formulation.
Interventions
DRUGTG-2349 as the original formulation
single oral dose under fed condition
DRUGTG-2349 as a new capsule formulation
single oral dose under fed condition
Sponsors
TaiGen Biotechnology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
at Screening 1. East Asian or Caucasian subjects, male or female, and 18 to 40 years of age inclusive 2. Body mass index (BMI) in the range of 19.0 to 30.0 kg/m2 and body weight ≥ 50 kg inclusive 3. In general good physical and mental health status on the basis of a medical history review, medical evaluation including vital signs and physical examination, 12-lead ECG, and laboratory results at screening 4. For females, one of the following criteria must be fulfilled: (1)At least 1 year post menopausal, or (2)Surgically sterile, or (3)Willing to use a double-barrier method (intrauterine device \[IUD\] plus condom, spermicidal gel plus condom) of contraception from screening until 30 days after the last dose of study drug; 5.Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from screening until 30 days after the last dose of study drug 6.Willing to abstain from caffeine- or xanthine-containing beverages (including coffee and tea), alcohol, grapefruit juice, and Seville oranges during the stay-on-site period 7.Willing and able to provide written informed consent
Exclusion criteria
at Screening 1. Positive serological test for IgM anti-HAV antibody, HbsAg, or anti-HCV antibody at screening 2. Positive ELISA test for HIV-1 or HIV-2 at screening 3. Any of the following abnormal laboratory values at screening: Hemoglobin (Hb) \<12.0g/dL for women and \<13.0g/dL for men, white blood cell count (WBC) \<3,000 cells/mm3, absolute neutrophil count \<1,500 cells/mm3, platelet count \<100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 xULN, INR (International Normalized Ratios for prothrombin time) ≥1.5 xULN 4. Any abnormal laboratory values that are considered clinically significant by the Investigator at screening 5. QTcF greater than 450 msec for females and 430 msec for males at screening 6. History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome 7. History of seizures, epilepsy, cardiovascular, diabetes, or cancer (except basal cell carcinoma) 8. History or family history of prolonged QT interval or family history of sudden cardiac death at a young age (\< 30 years ) 9. History of drug allergy or hypersensitivity, especially to sulfa drugs 10. History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use within 6 months prior to first dose of study drug administration 11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or who have any history of suicide attempt or depression 12. Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration 13. Pregnant or breast-feeding 14. Use of tobacco or nicotine-containing products within 30 days prior to first dose of study drug administration 15. Use of concomitant medication, including herbal remedies and dietary supplements (except for paracetamol/acetaminophen, ibuprofen, and hormonal contraceptives) within 14 days prior to first dose of study drug administration 16. Received any other investigational drug within 30 days prior to first dose of study drug administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary pharmacokinetic parameters: AUC0-t, AUC0-inf and Cmax | 120 hours after administration of study drug in each session |
Secondary
| Measure | Time frame |
|---|---|
| Secondary pharmacokinetic parameters:Tmax, t1/2, CL/F, V/F and λz | 120 hours after administration of study drug in each session |
| Urine pharmacokinetic parameters: Urine Ae% | 120 hours after administration of study drug in each session |
| Stool pharmacokinetic parameters: Stool Ae% | 120 hours after administration of study drug in each session |
| Safety parameters: Incidence and severity of AEs, changes from baseline in safety laboratory values, 12-lead ECG parameters, vital signs, and physical examination. | approximately 7 weeks |
Countries
United States
Outcome results
None listed